Written by Amirah Al Idrus
Sangamo’s struck another central nervous system deal—this time, it’s teaming up with Novartis on neurodevelopmental disorders. $75 million is changing hands upfront, but Sangamo could pick up an additional $720 million in milestones over the three-year deal.
Novartis grabs the rights to gene-regulating treatments for up to three genes involved in neurodevelopmental disorders, including intellectual disability and autism spectrum disorder. The programs will be based on Sangamo’s zinc finger platform that’s designed to repress or boost the expression of specific genes to bring about a therapeutic effect and change the course of disease.
“Partnering Sangamo’s proprietary technology with Novartis’ deep experience in neuroscience drug development is a powerful combination which expands Sangamo’s pipeline and allows us to tackle challenging neurodevelopmental conditions,” said Sangamo CEO Sandy Macrae in a statement. “Our goal in this collaboration is to create genomic medicines for patients with neurodevelopmental disorders, such as autism, that can potentially alter the natural history of these complex lifelong disorders.”
Read more here.